193 related articles for article (PubMed ID: 24898513)
1. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.
Wang N; Liu T; Sofiadis A; Juhlin CC; Zedenius J; Höög A; Larsson C; Xu D
Cancer; 2014 Oct; 120(19):2965-79. PubMed ID: 24898513
[TBL] [Abstract][Full Text] [Related]
2. TERT promoter mutation in adult granulosa cell tumor of the ovary.
Pilsworth JA; Cochrane DR; Xia Z; Aubert G; Färkkilä AEM; Horlings HM; Yanagida S; Yang W; Lim JLP; Wang YK; Bashashati A; Keul J; Wong A; Norris K; Brucker SY; Taran FA; Krämer B; Staebler A; van Meurs H; Oliva E; Shah SP; Kommoss S; Kommoss F; Gilks CB; Baird DM; Huntsman DG
Mod Pathol; 2018 Jul; 31(7):1107-1115. PubMed ID: 29449679
[TBL] [Abstract][Full Text] [Related]
3. Spectrum of TERT promoter mutations and mechanisms of activation in thyroid cancer.
Panebianco F; Nikitski AV; Nikiforova MN; Nikiforov YE
Cancer Med; 2019 Oct; 8(13):5831-5839. PubMed ID: 31408918
[TBL] [Abstract][Full Text] [Related]
4. Role of GPER1, EGFR and CXCR1 in differentiating between malignant follicular thyroid carcinoma and benign follicular thyroid adenoma.
Zhao L; Zhu XY; Jiang R; Xu M; Wang N; Chen GG; Liu ZM
Int J Clin Exp Pathol; 2015; 8(9):11236-47. PubMed ID: 26617848
[TBL] [Abstract][Full Text] [Related]
5. TERT C228T mutation in non-malignant bladder urothelium is associated with intravesical recurrence for patients with non-muscle invasive bladder cancer.
Hayashi Y; Fujita K; Nojima S; Tomiyama E; Matsushita M; Koh Y; Nakano K; Wang C; Ishizuya Y; Kato T; Hatano K; Kawashima A; Ujike T; Uemura M; Imamura R; Morii E; Nonomura N
Mol Oncol; 2020 Oct; 14(10):2375-2383. PubMed ID: 32533903
[TBL] [Abstract][Full Text] [Related]
6. TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma.
Spiegl-Kreinecker S; Lötsch D; Neumayer K; Kastler L; Gojo J; Pirker C; Pichler J; Weis S; Kumar R; Webersinke G; Gruber A; Berger W
Neuro Oncol; 2018 Nov; 20(12):1584-1593. PubMed ID: 30010853
[TBL] [Abstract][Full Text] [Related]
7. Detection of TERT promoter mutation in serum cell-free DNA using wild-type blocking PCR combined with Sanger sequencing in hepatocellular carcinoma.
Akuta N; Suzuki F; Kobayashi M; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Suzuki Y; Kumada H
J Med Virol; 2020 Dec; 92(12):3604-3608. PubMed ID: 32100879
[TBL] [Abstract][Full Text] [Related]
8. Association of Ultrasonography Features of Follicular Thyroid Carcinoma With Tumor Invasiveness and Prognosis Based on WHO Classification and TERT Promoter Mutation.
Kim MK; Park H; Oh YL; Shin JH; Kim TH; Hahn SY
Korean J Radiol; 2024 Jan; 25(1):103-112. PubMed ID: 38184773
[TBL] [Abstract][Full Text] [Related]
9. Reactivation of telomerase in cancer.
Akincilar SC; Unal B; Tergaonkar V
Cell Mol Life Sci; 2016 Apr; 73(8):1659-70. PubMed ID: 26846696
[TBL] [Abstract][Full Text] [Related]
10. Thyroid carcinoma-featured telomerase activation and telomere maintenance: Biology and translational/clinical significance.
Yuan X; Yuan H; Zhang N; Liu T; Xu D
Clin Transl Med; 2022 Nov; 12(11):e1111. PubMed ID: 36394204
[TBL] [Abstract][Full Text] [Related]
11. Selection Criteria for Completion Thyroidectomy in Follicular Thyroid Carcinoma Using Primary Tumor Size and TERT Promoter Mutational Status.
Park H; Heo J; Ki CS; Shin JH; Oh YL; Son YI; Kim JS; Kim SW; Chung JH; Kim TY; Kim TH; Kim JH
Ann Surg Oncol; 2023 May; 30(5):2916-2925. PubMed ID: 36637642
[TBL] [Abstract][Full Text] [Related]
12. Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup.
Pirker C; Bilecz A; Grusch M; Mohr T; Heidenreich B; Laszlo V; Stockhammer P; Lötsch-Gojo D; Gojo J; Gabler L; Spiegl-Kreinecker S; Dome B; Steindl A; Klikovits T; Hoda MA; Jakopovic M; Samarzija M; Mohorcic K; Kern I; Kiesel B; Brcic L; Oberndorfer F; Müllauer L; Klepetko W; Schmidt WM; Kumar R; Hegedus B; Berger W
Clin Cancer Res; 2020 Jul; 26(14):3819-3830. PubMed ID: 32317288
[TBL] [Abstract][Full Text] [Related]
13. Interplay between TERT promoter mutations and methylation culminates in chromatin accessibility and TERT expression.
Salgado C; Roelse C; Nell R; Gruis N; van Doorn R; van der Velden P
PLoS One; 2020; 15(4):e0231418. PubMed ID: 32267900
[TBL] [Abstract][Full Text] [Related]
14. Nuclear-specific accumulation of
Hellgren LS; Olsson A; Kaufeldt A; Paulsson JO; Hysek M; Stenman A; Zedenius J; Larsson C; Höög A; Juhlin CC
J Clin Pathol; 2021 May; 75(10):658-62. PubMed ID: 34011619
[TBL] [Abstract][Full Text] [Related]
15. Pervasive promoter hypermethylation of silenced TERT alleles in human cancers.
Esopi D; Graham MK; Brosnan-Cashman JA; Meyers J; Vaghasia A; Gupta A; Kumar B; Haffner MC; Heaphy CM; De Marzo AM; Meeker AK; Nelson WG; Wheelan SJ; Yegnasubramanian S
Cell Oncol (Dordr); 2020 Oct; 43(5):847-861. PubMed ID: 32468444
[TBL] [Abstract][Full Text] [Related]
16. Characterization of human telomerase reverse transcriptase promoter methylation and transcription factor binding in differentiated thyroid cancer cell lines.
Avin BA; Wang Y; Gilpatrick T; Workman RE; Lee I; Timp W; Umbricht CB; Zeiger MA
Genes Chromosomes Cancer; 2019 Aug; 58(8):530-540. PubMed ID: 30664813
[TBL] [Abstract][Full Text] [Related]
17. Characterization of Allele-Specific Regulation of Telomerase Reverse Transcriptase in Promoter Mutant Thyroid Cancer Cell Lines.
McKelvey BA; Gilpatrick T; Wang Y; Timp W; Umbricht CB; Zeiger MA
Thyroid; 2020 Oct; 30(10):1470-1481. PubMed ID: 32228178
[No Abstract] [Full Text] [Related]
18. Role of hypermethylated SLC5A8 in follicular thyroid cancer diagnosis and prognosis prediction.
Yang Y; Liao C; Yang Q; Li Y; Tang Y; Xu B
World J Surg Oncol; 2023 Nov; 21(1):367. PubMed ID: 38007446
[TBL] [Abstract][Full Text] [Related]
19. Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer.
Avogbe PH; Manel A; Vian E; Durand G; Forey N; Voegele C; Zvereva M; Hosen MI; Meziani S; De Tilly B; Polo G; Lole O; Francois P; Delhomme TM; Carreira C; Monteiro-Reis S; Henrique R; Abedi-Ardekani B; Byrnes G; Foll M; Weiderpass E; McKay J; Jeronimo C; Scelo G; Le Calvez-Kelm F
EBioMedicine; 2019 Jun; 44():431-438. PubMed ID: 31122840
[TBL] [Abstract][Full Text] [Related]
20. The role of telomerase reverse transcriptase (TERT) promoter mutations in prognosis in bladder cancer.
Wan S; Liu X; Hua W; Xi M; Zhou Y; Wan Y
Bioengineered; 2021 Dec; 12(1):1495-1504. PubMed ID: 33938397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
